インフルエンザ に 対抗 する 捕らえる 抑制 剤
1Department of Microbiology; Global Health and Emerging Pathogens Institute; and Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10128, USA.
Cell
|June 1, 2019
まとめ
科学 者 たち は インフルエンザ ウイルス を 標的 と する 新しい 薬 を 開発 し た
科学分野:
- ウイルス学
- 分子生物学
背景:
- インフルエンザウイルスの転写は,ウイルスのmRNAが宿主細胞の5'キャップされたmRNA断片をプライマーとして利用するプロセスであるキャップスナッチングに依存しています.
- このキャップスナッチングメカニズムは,ウイルスのRNA合成に不可欠なウイルス内核酵素によって媒介されます.
研究 の 目的:
- カップスナッチングに関与するウイルス内核酵素を阻害する治療の可能性を調査する.
- インフルエンザ感染の治療のための新しい抑制剤を評価する.
主な方法:
- ウイルス内核酵素を標的とする特定の阻害剤の開発
- インフルエンザの治療における阻害剤の有効性の評価 (暗示)
主要な成果:
- 新しく開発された阻害剤は,インフルエンザに対する治療効果を示した.
- ウイルスのエンドヌクレアースの抑制は,ウイルスのmRNA転写を効果的に妨害する.
結論:
- ウイルスのエンドヌクレアスをターゲットにすることは インフルエンザ治療の有効な戦略です
- この新しい阻害剤は,抗インフルエンザ治療薬として有望である.
関連する概念動画
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Dipeptidyl Peptidase 4 Inhibitors
616
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
616
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.4K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
580
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
580
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
553
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
553


